A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight (VLBW) Neonates for the Prevention of Staphylococcal Sepsis.

Trial Profile

A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight (VLBW) Neonates for the Prevention of Staphylococcal Sepsis.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 29 Nov 2012

At a glance

  • Drugs Pagibaximab (Primary)
  • Indications Sepsis; Staphylococcal infections
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 28 Apr 2012 Status changed from active, no longer recruiting to completed as reported by United Kingdom Clinical Research Network.
    • 15 Mar 2012 Additional locations added as reported by European Clinical Trials Database record.
    • 15 Mar 2012 This trial has been completed in Germany, Italy, Spain, United Kingdom and recruiting in Spain.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top